Related Experiment Video
Updated: Sep 4, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
[Modification of pulmonary hypertension in patients with chronic obstructive lung diseases using calcium antagonists
J Schauer1, W Himmel, H Orschekowski
1Abteilung für Pneumologie, Bereiches Medizin Karl-Marx-Universität Leipzig.
Abstract:
Since the life expectancy of the patients with chronic obstructive lung diseases (COLD) is essentially determined by the size of the pulmonary hypertension, today the efforts are directed to an early and effective therapy of the precapillary hypertension. Apart from a treatment of the pulmonary basic disease the therapy with vasodilators stands in the centre of interest. The influence on mean pressure of the pulmonary artery and vascular resistance of the lung by verapamil (39 patients) and nifedipine (21 patients) was investigated. In patients with latent pulmonary hypertension the two calcium antagonists showed a reduction of the pressure of the pulmonary arteries and vascular resistance of the lungs, which was more distinct when nifedipine was given. An influence on the haemodynamic parameters in patients with manifest pulmonary hypertension could not be ascertained. In correspondence with the findings in literature the results show that the use of calcium antagonists for part of the patients with precapillary hypertension appears as an enrichment of the therapeutic possibilities. At present a prerequisite for this, however, are still individual haemodynamic investigations. The question of the effectivity of a long-term therapy is not yet satisfactorily clarified.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

